CytoMed Therapeutics shares surge 38.84% after-hours on advancements in cell therapies and strategic partnerships.

CytoMed Therapeutics surged 38.84% in after-hours trading following a Bloomberg report highlighting the company’s advancements in cell therapies and strategic partnerships. The stock’s sharp rise was driven by positive sentiment around its Natural Killer cell therapy pipeline, robust financial management—evidenced by $10M in assets and a balanced leverage ratio of 1.1—and collaboration with Enterprise Singapore. Analysts noted that these developments, combined with a stable revenue base and prudent debt strategy, reinforced investor confidence in the firm’s sustainable growth trajectory. The market reaction underscored optimism about the company’s innovative potential and long-term value creation in the biopharma sector.